Myeloid subsets impede the efficacy of anti-PD1 therapy in patients with advanced gastric cancer (WJOG10417GTR study).

J Immunother Cancer · 2024 · PMC11535716 · PMID 39489543

Europe PMC DOI

hedged sentence

0.0520

closest p · 1.0× alpha

0.0520

boldest claim

The sentences

showed a trendp=0.052so close (0.05 < p ≤ 0.1)

However, high levels of the PDL1 + CTLA4 + LAG3 + subset both before (mPFS: 1.6 months vs 2.1 months in low levels, HR=1.971, p=0.010) and after treatment (mPFS: 2.9 months vs 4.5 months, HR=2.246, p=0.008) were also significantly associated with shorter PFS and showed a trend towards association with shorter OS (mOS: 9.0 months vs 15.6 months, HR=2.164, p=0.052; online supplemental figure S5B ).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.